Potassium Citrate Tablet, Extended Release
Product Images NDC 31722-130

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Potassium Citrate (NDC 31722-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 Meq-100s (10 Meq 100s)

Potassium Citrate Extended-Release Tablets USP 10 mEq (1080 mg) per tablet in a 100-tablet package. The label shows the product is manufactured by Ascent Pharmaceuticals, Inc. and labeled for Camber Pharmaceuticals, Inc. The tablets are uncoated, capsule-shaped, and off white to tan yellowish. The label includes storage information and a barcode.*

FDA Label Image

15 Meq-100s (15 Meq 100s)

Potassium Citrate Extended-Release Tablets, USP 15 mEq (1620 mg) per tablet oral dosage form. The label shows a package containing 100 tablets, Rx only, with the labeler as Camber Pharmaceuticals, Inc. The design includes a barcode, NDC 31722-132-01, and mentions manufacturing by Ascent Pharmaceuticals, Inc.*

FDA Label Image

5 Meq-100s (5 Meq 100s)

Potassium Citrate Extended-Release Tablets, USP 5 mEq (540 mg) per tablet. The label indicates a prescription drug with 100 tablets per container, manufactured by Camber Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. Additional storage and handling instructions are included.*

FDA Label Image

Structure (Structure)

Chemical structure of potassium citrate hydrate showing the citrate backbone with three potassium carboxylate groups and one water molecule of hydration.*

FDA Label Image

Table 1.

Data table titled 'Effect of Potassium Citrate In Patients With Calcium Oxalate Nephrolithiasis' showing stones formed per year across four patient groups at baseline, on treatment, remission percentages, and any decrease percentages, with a total summary row. Remission is defined as patients remaining free of newly formed stones during treatment.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.